Related Experiment Videos
Autologous graft-versus-host disease
1Fifth Department of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
International Journal of Hematology
|February 1, 1997
Summary
Cyclosporine A treatment after autologous bone marrow transplantation (autoBMT) can cause autologous graft-versus-host disease (autoGvHD). This condition may offer a graft-versus-tumor effect beneficial for patients.
Area of Science:
- Immunology
- Transplantation Medicine
- Oncology
Background:
- Autologous bone marrow transplantation (autoBMT) is a therapeutic strategy.
- Immunosuppressive drugs like cyclosporine A are used post-transplant.
- Acute graft-versus-host disease (GvHD) is a known complication of allogeneic BMT.
Purpose of the Study:
- To investigate the induction and mechanisms of autologous graft-versus-host disease (autoGvHD) after autoBMT.
- To explore the potential therapeutic benefits of autoGvHD in the context of graft-versus-tumor effects.
Main Methods:
- Treatment of patients undergoing autoBMT with cyclosporine A.
- Monitoring for the development of autoGvHD.
- Analysis of T cell populations and their recognition of self MHC class II antigens.
- Evaluation of peripheral autoregulatory mechanisms.
Main Results:
- Cyclosporine A treatment following autoBMT induces autoGvHD.
- AutoGvHD development is linked to autoreactive T cells targeting self MHC class II.
- A T-cell-dependent peripheral autoregulatory mechanism is eliminated during autoGvHD induction.
Conclusions:
- AutoGvHD can be induced by cyclosporine A in autoBMT settings.
- The emergence of autoreactive T cells and loss of regulation contribute to autoGvHD.
- Induced autoGvHD may provide a graft-versus-tumor effect, potentially benefiting cancer patients.